KORU Medical Systems, Inc. (KRMD)

The investment case here is a classic tale of a turnaround story fighting against persistent execution risks. Fundamentally, the company is showing signs of life with revenue growing 22% year-over-year and gross margins holding steady above 60%, which is a strong operational signal for a medical device firm. However, the bottom line remains deeply troubled; operating losses are widening, and the company is burning cash despite generating some free cash flow. This disconnect between top-line growth and bottom-line deterioration creates a fragile valuation where the market is pricing in a need for profitability to materialize quickly. The price action reflects this tension. While the stock has rallied significantly over the last decade, the recent trajectory shows volatility without a clear breakout, trading below its 200-day average. The statistical forecast model leans slightly bearish for the next 45 days, suggesting that the immediate momentum might fade as the market digests the continued losses. Options activity reinforces a cautious stance, with sellers placing heavy hedges at lower strikes ($2.50) rather than buyers aggressively betting on a massive surge. For the long term, the business quality is decent given the niche focus and improving revenue, but the financial health is precarious. The lack of a dividend and negative returns on equity mean there is no safety net if the turnaround stalls. Until operating income turns positive and the balance sheet strengthens, this remains a speculative hold rather than a core buy. The current rating reflects a slight positive lean due to the revenue growth, but the widening losses prevent a higher conviction score.